Answers are grounded in this paper and cite their sources.
With the use of a DA to LEW rat renal allograft model, the ability of cyclosporin A to influence a second-set rejection was investigated. Sensitization of LEW rats was accomplished by performing DA to LEW skin grafts 4 to 5 weeks before kidney allografting. Cyclosporin A was given to sensitized rats in doses of 10 or 25 mg/kg/day for 14 days from the time of renal transplantation. Neither dose was nearly as effective in prolonging kidney graft survival in sensitized rats as the 10 mg/kg/day dose was in prolonging kidney graft survival in unsensitized rats. In the 25 mg/kg/day dose, cyclosporin A was capable of suppressing antibody formation to the graft in sensitized recipients despite the presence of donor-specific antibodies at the time of renal transplantation. The 10 mg/kg/day dose of cyclosporin A did not, however, suppress antibody formation after renal transplantation in sensitized recipients. In both sensitized and unsensitized rats cyclosporin A was effective in ameliorating the histological findings of arterial fibrinoid necrosis and glomerular necrosis in the renal allografts. In neither sensitized nor unsensitized rats did cyclosporin A effect the mononuclear cell infiltration of the renal allograft.
No takes yet. Share an insight, caveat, or question.
HOMAN et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: